 Brian Cole
Concepts (795)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cartilage, Articular | 119 | 2021 | 586 | 29.100 |
Why?
| | Knee Joint | 139 | 2022 | 775 | 24.830 |
Why?
| | Menisci, Tibial | 64 | 2022 | 166 | 21.640 |
Why?
| | Knee Injuries | 73 | 2020 | 220 | 19.280 |
Why?
| | Osteoarthritis, Knee | 53 | 2022 | 366 | 15.090 |
Why?
| | Arthroscopy | 139 | 2022 | 781 | 15.010 |
Why?
| | Cartilage Diseases | 38 | 2020 | 76 | 14.200 |
Why?
| | Platelet-Rich Plasma | 41 | 2021 | 67 | 13.690 |
Why?
| | Shoulder Joint | 95 | 2022 | 560 | 12.020 |
Why?
| | Bone Transplantation | 40 | 2021 | 231 | 11.260 |
Why?
| | Anterior Cruciate Ligament Reconstruction | 56 | 2022 | 222 | 10.310 |
Why?
| | Rotator Cuff | 52 | 2022 | 252 | 10.230 |
Why?
| | Osteotomy | 28 | 2020 | 161 | 10.070 |
Why?
| | Allografts | 48 | 2022 | 171 | 9.600 |
Why?
| | Orthopedic Procedures | 47 | 2021 | 322 | 9.230 |
Why?
| | Humans | 516 | 2022 | 31481 | 8.680 |
Why?
| | Transplantation, Homologous | 68 | 2022 | 292 | 8.680 |
Why?
| | Cartilage | 29 | 2021 | 168 | 7.790 |
Why?
| | Chondrocytes | 44 | 2020 | 216 | 7.540 |
Why?
| | Tibia | 33 | 2020 | 266 | 6.930 |
Why?
| | Joint Instability | 49 | 2021 | 374 | 6.920 |
Why?
| | Treatment Outcome | 139 | 2022 | 3910 | 6.130 |
Why?
| | Adult | 206 | 2022 | 9779 | 6.120 |
Why?
| | Femur | 36 | 2022 | 389 | 6.010 |
Why?
| | Reoperation | 59 | 2022 | 938 | 5.670 |
Why?
| | Male | 249 | 2021 | 17583 | 5.490 |
Why?
| | Female | 229 | 2022 | 18253 | 5.070 |
Why?
| | Return to Work | 12 | 2021 | 53 | 5.030 |
Why?
| | Shoulder | 34 | 2022 | 156 | 5.020 |
Why?
| | Tendon Injuries | 25 | 2021 | 189 | 4.930 |
Why?
| | Young Adult | 90 | 2021 | 2277 | 4.880 |
Why?
| | Follow-Up Studies | 71 | 2021 | 2028 | 4.780 |
Why?
| | Middle Aged | 180 | 2022 | 11209 | 4.730 |
Why?
| | Biological Products | 8 | 2022 | 38 | 4.590 |
Why?
| | Arthroplasty, Subchondral | 12 | 2018 | 27 | 4.580 |
Why?
| | Athletic Injuries | 26 | 2020 | 182 | 4.490 |
Why?
| | Adolescent | 87 | 2022 | 2667 | 4.450 |
Why?
| | Wound Healing | 23 | 2021 | 175 | 4.390 |
Why?
| | Retrospective Studies | 86 | 2022 | 3591 | 4.290 |
Why?
| | Anterior Cruciate Ligament | 40 | 2022 | 268 | 4.240 |
Why?
| | Arthroplasty | 28 | 2020 | 125 | 4.200 |
Why?
| | Tenodesis | 21 | 2022 | 143 | 4.130 |
Why?
| | Osteoarthritis | 23 | 2022 | 369 | 4.090 |
Why?
| | Suture Techniques | 22 | 2021 | 138 | 3.990 |
Why?
| | Osteochondritis Dissecans | 9 | 2019 | 27 | 3.740 |
Why?
| | Transplantation, Autologous | 46 | 2021 | 223 | 3.710 |
Why?
| | Injections, Intra-Articular | 26 | 2022 | 81 | 3.520 |
Why?
| | Hyaluronic Acid | 16 | 2021 | 108 | 3.430 |
Why?
| | Patellofemoral Joint | 12 | 2020 | 39 | 3.330 |
Why?
| | Pain | 21 | 2022 | 336 | 3.330 |
Why?
| | Patient Satisfaction | 22 | 2021 | 315 | 3.320 |
Why?
| | Orthopedics | 12 | 2021 | 133 | 3.310 |
Why?
| | Shoulder Dislocation | 15 | 2021 | 84 | 3.290 |
Why?
| | Fractures, Stress | 5 | 2021 | 20 | 3.050 |
Why?
| | Range of Motion, Articular | 55 | 2020 | 703 | 3.030 |
Why?
| | Magnetic Resonance Imaging | 33 | 2022 | 1273 | 2.940 |
Why?
| | Sports Medicine | 7 | 2022 | 42 | 2.760 |
Why?
| | Biomechanical Phenomena | 50 | 2020 | 719 | 2.690 |
Why?
| | Pain, Postoperative | 12 | 2022 | 306 | 2.550 |
Why?
| | Arthroplasty, Replacement, Knee | 13 | 2021 | 668 | 2.480 |
Why?
| | Reconstructive Surgical Procedures | 20 | 2021 | 226 | 2.460 |
Why?
| | Recovery of Function | 23 | 2020 | 309 | 2.400 |
Why?
| | Pain Measurement | 27 | 2022 | 476 | 2.390 |
Why?
| | Joint Diseases | 10 | 2020 | 114 | 2.360 |
Why?
| | Postoperative Complications | 25 | 2021 | 1083 | 2.330 |
Why?
| | Suture Anchors | 13 | 2019 | 59 | 2.280 |
Why?
| | Anesthetics, Local | 6 | 2019 | 86 | 2.160 |
Why?
| | Tendons | 19 | 2022 | 212 | 2.130 |
Why?
| | Humeral Head | 7 | 2021 | 26 | 2.110 |
Why?
| | Chondrogenesis | 7 | 2020 | 30 | 1.990 |
Why?
| | Cadaver | 42 | 2020 | 356 | 1.880 |
Why?
| | Debridement | 18 | 2018 | 99 | 1.870 |
Why?
| | Graft Survival | 11 | 2020 | 111 | 1.860 |
Why?
| | Aged | 78 | 2021 | 10295 | 1.860 |
Why?
| | Radiography | 25 | 2020 | 717 | 1.800 |
Why?
| | Prospective Studies | 35 | 2022 | 1934 | 1.770 |
Why?
| | Postoperative Period | 22 | 2022 | 295 | 1.740 |
Why?
| | Ligaments, Articular | 12 | 2022 | 96 | 1.730 |
Why?
| | Scapula | 12 | 2020 | 81 | 1.700 |
Why?
| | Cohort Studies | 33 | 2022 | 2014 | 1.700 |
Why?
| | Tendinopathy | 10 | 2021 | 62 | 1.660 |
Why?
| | Sutures | 5 | 2021 | 44 | 1.620 |
Why?
| | Growth Plate | 2 | 2020 | 29 | 1.580 |
Why?
| | Bone Screws | 7 | 2019 | 178 | 1.520 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 378 | 1.510 |
Why?
| | Physical Examination | 15 | 2019 | 116 | 1.470 |
Why?
| | Psychometrics | 4 | 2021 | 287 | 1.470 |
Why?
| | Stem Cell Transplantation | 4 | 2020 | 54 | 1.460 |
Why?
| | Tissue Engineering | 6 | 2012 | 50 | 1.430 |
Why?
| | Absorbable Implants | 6 | 2014 | 25 | 1.420 |
Why?
| | Elbow Joint | 8 | 2015 | 132 | 1.410 |
Why?
| | Bone Marrow | 8 | 2022 | 68 | 1.410 |
Why?
| | Athletes | 11 | 2022 | 77 | 1.400 |
Why?
| | Animals | 42 | 2022 | 5312 | 1.370 |
Why?
| | Treatment Failure | 15 | 2020 | 187 | 1.370 |
Why?
| | Research Design | 5 | 2020 | 238 | 1.370 |
Why?
| | Intra-Articular Fractures | 5 | 2020 | 14 | 1.310 |
Why?
| | Muscle, Skeletal | 17 | 2022 | 385 | 1.300 |
Why?
| | United States | 31 | 2021 | 2539 | 1.290 |
Why?
| | Adrenal Cortex Hormones | 5 | 2020 | 100 | 1.280 |
Why?
| | Bone Malalignment | 3 | 2016 | 20 | 1.270 |
Why?
| | Tomography, X-Ray Computed | 18 | 2020 | 891 | 1.260 |
Why?
| | Upper Extremity | 9 | 2021 | 46 | 1.250 |
Why?
| | Quality of Life | 17 | 2022 | 663 | 1.250 |
Why?
| | Activities of Daily Living | 11 | 2022 | 495 | 1.240 |
Why?
| | Time Factors | 25 | 2021 | 1902 | 1.220 |
Why?
| | Quality Improvement | 3 | 2019 | 173 | 1.200 |
Why?
| | Patient Selection | 10 | 2020 | 264 | 1.190 |
Why?
| | Tissue Transplantation | 6 | 2016 | 20 | 1.190 |
Why?
| | Baseball | 10 | 2017 | 104 | 1.190 |
Why?
| | Viscosupplementation | 4 | 2020 | 8 | 1.160 |
Why?
| | Postoperative Care | 11 | 2020 | 141 | 1.150 |
Why?
| | Viscosupplements | 4 | 2020 | 13 | 1.150 |
Why?
| | Imaging, Three-Dimensional | 14 | 2020 | 233 | 1.130 |
Why?
| | Health Knowledge, Attitudes, Practice | 2 | 2018 | 230 | 1.120 |
Why?
| | Autografts | 7 | 2021 | 28 | 1.110 |
Why?
| | Hyaline Cartilage | 6 | 2020 | 15 | 1.100 |
Why?
| | Bupivacaine | 3 | 2012 | 55 | 1.090 |
Why?
| | Arthralgia | 11 | 2020 | 120 | 1.070 |
Why?
| | Surgeons | 3 | 2021 | 84 | 1.060 |
Why?
| | Bone and Bones | 5 | 2018 | 110 | 1.050 |
Why?
| | Preoperative Period | 6 | 2020 | 73 | 1.010 |
Why?
| | Reproducibility of Results | 13 | 2021 | 886 | 1.000 |
Why?
| | Recurrence | 16 | 2021 | 389 | 1.000 |
Why?
| | X-Ray Microtomography | 4 | 2021 | 71 | 1.000 |
Why?
| | Glenoid Cavity | 5 | 2015 | 33 | 0.980 |
Why?
| | Intercellular Signaling Peptides and Proteins | 4 | 2013 | 59 | 0.980 |
Why?
| | Computer Simulation | 10 | 2022 | 249 | 0.970 |
Why?
| | Humerus | 10 | 2019 | 107 | 0.970 |
Why?
| | Hemiarthroplasty | 4 | 2022 | 31 | 0.970 |
Why?
| | Patella | 10 | 2022 | 77 | 0.950 |
Why?
| | Ossification, Heterotopic | 2 | 2022 | 40 | 0.940 |
Why?
| | Acromion | 6 | 2018 | 27 | 0.900 |
Why?
| | Extracellular Matrix | 2 | 2021 | 92 | 0.890 |
Why?
| | Venous Thrombosis | 2 | 2017 | 51 | 0.890 |
Why?
| | Arthritis | 5 | 2016 | 113 | 0.870 |
Why?
| | Arm | 9 | 2022 | 78 | 0.840 |
Why?
| | Anesthesia, Dental | 2 | 2019 | 2 | 0.840 |
Why?
| | Soft Tissue Injuries | 3 | 2016 | 17 | 0.830 |
Why?
| | Child | 14 | 2022 | 1572 | 0.830 |
Why?
| | Incidence | 11 | 2019 | 829 | 0.820 |
Why?
| | Double-Blind Method | 7 | 2022 | 559 | 0.800 |
Why?
| | Amnion | 2 | 2020 | 6 | 0.800 |
Why?
| | Databases, Factual | 9 | 2019 | 391 | 0.790 |
Why?
| | Cell Separation | 1 | 2020 | 44 | 0.780 |
Why?
| | Carticaine | 1 | 2019 | 1 | 0.780 |
Why?
| | Pulmonary Embolism | 2 | 2018 | 57 | 0.770 |
Why?
| | Stem Cells | 1 | 2020 | 52 | 0.770 |
Why?
| | Exercise Therapy | 4 | 2017 | 116 | 0.760 |
Why?
| | Basketball | 3 | 2016 | 10 | 0.760 |
Why?
| | Genu Varum | 1 | 2019 | 3 | 0.760 |
Why?
| | Rupture | 14 | 2021 | 115 | 0.760 |
Why?
| | Fibrin Tissue Adhesive | 3 | 2019 | 7 | 0.750 |
Why?
| | Cumulative Trauma Disorders | 3 | 2017 | 16 | 0.740 |
Why?
| | Leukocytes | 3 | 2016 | 50 | 0.740 |
Why?
| | Catheter Ablation | 4 | 2008 | 76 | 0.730 |
Why?
| | Muscle Strength | 5 | 2017 | 134 | 0.730 |
Why?
| | Nerve Block | 1 | 2019 | 58 | 0.730 |
Why?
| | Shoulder Pain | 5 | 2017 | 57 | 0.720 |
Why?
| | Risk Factors | 21 | 2020 | 2664 | 0.720 |
Why?
| | Patellofemoral Pain Syndrome | 2 | 2017 | 3 | 0.700 |
Why?
| | Age Factors | 15 | 2021 | 943 | 0.690 |
Why?
| | Patient Outcome Assessment | 5 | 2018 | 50 | 0.690 |
Why?
| | Football | 5 | 2018 | 34 | 0.680 |
Why?
| | Stifle | 1 | 2018 | 12 | 0.680 |
Why?
| | Evidence-Based Medicine | 8 | 2020 | 239 | 0.660 |
Why?
| | Patellar Ligament | 7 | 2022 | 50 | 0.640 |
Why?
| | Regeneration | 3 | 2011 | 30 | 0.640 |
Why?
| | Soccer | 3 | 2018 | 17 | 0.630 |
Why?
| | Workers' Compensation | 6 | 2021 | 50 | 0.630 |
Why?
| | Health Literacy | 1 | 2018 | 102 | 0.630 |
Why?
| | Bone Morphogenetic Proteins | 4 | 2011 | 100 | 0.630 |
Why?
| | Patient Preference | 1 | 2017 | 36 | 0.630 |
Why?
| | Physical Therapy Modalities | 6 | 2019 | 70 | 0.620 |
Why?
| | Synovial Fluid | 2 | 2017 | 138 | 0.620 |
Why?
| | Second-Look Surgery | 5 | 2020 | 13 | 0.610 |
Why?
| | Stress, Mechanical | 9 | 2020 | 198 | 0.610 |
Why?
| | Sodium Chloride | 1 | 2016 | 44 | 0.610 |
Why?
| | Lidocaine | 3 | 2019 | 44 | 0.600 |
Why?
| | Prognosis | 10 | 2019 | 1028 | 0.600 |
Why?
| | Lysholm Knee Score | 4 | 2021 | 6 | 0.590 |
Why?
| | Cytokines | 7 | 2018 | 364 | 0.580 |
Why?
| | Time-to-Treatment | 2 | 2015 | 37 | 0.580 |
Why?
| | Randomized Controlled Trials as Topic | 13 | 2020 | 375 | 0.570 |
Why?
| | Patient Education as Topic | 2 | 2017 | 192 | 0.570 |
Why?
| | Prostheses and Implants | 5 | 2008 | 166 | 0.570 |
Why?
| | Tenotomy | 1 | 2015 | 16 | 0.570 |
Why?
| | Quadriceps Muscle | 4 | 2020 | 27 | 0.570 |
Why?
| | Weight-Bearing | 9 | 2018 | 193 | 0.570 |
Why?
| | Tissue Donors | 3 | 2019 | 79 | 0.560 |
Why?
| | Tissue Adhesives | 2 | 2019 | 11 | 0.560 |
Why?
| | Knee Prosthesis | 2 | 2016 | 237 | 0.550 |
Why?
| | Sterilization | 2 | 2014 | 10 | 0.550 |
Why?
| | Bone-Patellar Tendon-Bone Grafting | 7 | 2021 | 42 | 0.540 |
Why?
| | Multivariate Analysis | 10 | 2021 | 390 | 0.540 |
Why?
| | Analgesics, Opioid | 4 | 2022 | 211 | 0.540 |
Why?
| | Ontario | 3 | 2020 | 18 | 0.530 |
Why?
| | Cell Survival | 10 | 2020 | 181 | 0.530 |
Why?
| | Serial Publications | 1 | 2014 | 1 | 0.530 |
Why?
| | Collateral Ligaments | 2 | 2013 | 21 | 0.520 |
Why?
| | Transforming Growth Factor beta | 3 | 2008 | 126 | 0.520 |
Why?
| | Osteochondritis | 2 | 2011 | 4 | 0.520 |
Why?
| | Cryopreservation | 2 | 2018 | 25 | 0.520 |
Why?
| | Cost-Benefit Analysis | 5 | 2022 | 153 | 0.510 |
Why?
| | Aged, 80 and over | 20 | 2018 | 5234 | 0.510 |
Why?
| | Elbow | 5 | 2021 | 47 | 0.500 |
Why?
| | Chlorhexidine | 1 | 2014 | 54 | 0.500 |
Why?
| | Anti-Infective Agents, Local | 1 | 2014 | 50 | 0.500 |
Why?
| | Athletic Performance | 4 | 2020 | 22 | 0.490 |
Why?
| | Case-Control Studies | 9 | 2020 | 687 | 0.490 |
Why?
| | Gymnastics | 2 | 2010 | 5 | 0.490 |
Why?
| | Disease Models, Animal | 9 | 2021 | 832 | 0.480 |
Why?
| | Rabbits | 7 | 2015 | 326 | 0.470 |
Why?
| | Proteoglycans | 9 | 2019 | 419 | 0.460 |
Why?
| | Sex Factors | 6 | 2019 | 542 | 0.460 |
Why?
| | Drug Therapy, Combination | 2 | 2011 | 265 | 0.450 |
Why?
| | Random Allocation | 9 | 2019 | 164 | 0.450 |
Why?
| | Tissue and Organ Harvesting | 4 | 2005 | 25 | 0.450 |
Why?
| | Insulin-Like Growth Factor I | 2 | 2011 | 60 | 0.440 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2022 | 111 | 0.410 |
Why?
| | Pilot Projects | 6 | 2019 | 455 | 0.410 |
Why?
| | Cells, Cultured | 5 | 2020 | 802 | 0.410 |
Why?
| | Clinical Competence | 3 | 2019 | 274 | 0.410 |
Why?
| | Algorithms | 6 | 2020 | 412 | 0.400 |
Why?
| | Therapeutic Irrigation | 5 | 2013 | 69 | 0.400 |
Why?
| | Anti-Inflammatory Agents | 3 | 2014 | 109 | 0.400 |
Why?
| | Ulna | 1 | 2010 | 28 | 0.400 |
Why?
| | Rotation | 12 | 2018 | 158 | 0.390 |
Why?
| | Cattle | 8 | 2019 | 260 | 0.390 |
Why?
| | Fractures, Cartilage | 1 | 2010 | 4 | 0.390 |
Why?
| | Biocompatible Materials | 6 | 2016 | 112 | 0.390 |
Why?
| | Tendon Transfer | 3 | 2015 | 24 | 0.390 |
Why?
| | Arthroplasty, Replacement | 5 | 2014 | 147 | 0.390 |
Why?
| | Models, Animal | 6 | 2015 | 149 | 0.380 |
Why?
| | Fibrocartilage | 2 | 2015 | 9 | 0.370 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2010 | 300 | 0.370 |
Why?
| | Methylprednisolone | 1 | 2009 | 26 | 0.360 |
Why?
| | Demography | 2 | 2019 | 83 | 0.360 |
Why?
| | Hemostasis, Surgical | 2 | 2006 | 18 | 0.360 |
Why?
| | Brachial Plexus | 1 | 2008 | 4 | 0.350 |
Why?
| | Kaplan-Meier Estimate | 2 | 2019 | 230 | 0.350 |
Why?
| | Decompression, Surgical | 2 | 2012 | 146 | 0.340 |
Why?
| | Lower Extremity Deformities, Congenital | 1 | 2008 | 2 | 0.340 |
Why?
| | Child, Preschool | 2 | 2021 | 786 | 0.340 |
Why?
| | Freezing | 1 | 2008 | 14 | 0.340 |
Why?
| | Rats | 5 | 2020 | 966 | 0.340 |
Why?
| | Wounds and Injuries | 4 | 2019 | 58 | 0.340 |
Why?
| | Patient Positioning | 2 | 2020 | 35 | 0.330 |
Why?
| | Conflict of Interest | 2 | 2019 | 19 | 0.330 |
Why?
| | Patient Care Planning | 2 | 2005 | 58 | 0.330 |
Why?
| | Graft Rejection | 5 | 2014 | 84 | 0.330 |
Why?
| | Transcutaneous Electric Nerve Stimulation | 1 | 2007 | 3 | 0.330 |
Why?
| | Physician Incentive Plans | 1 | 2007 | 3 | 0.320 |
Why?
| | Lower Extremity | 2 | 2018 | 37 | 0.320 |
Why?
| | Patellar Dislocation | 2 | 2019 | 17 | 0.320 |
Why?
| | Salaries and Fringe Benefits | 1 | 2007 | 12 | 0.320 |
Why?
| | Tissue Scaffolds | 3 | 2015 | 27 | 0.320 |
Why?
| | Electric Stimulation | 1 | 2007 | 87 | 0.320 |
Why?
| | Decision Making | 2 | 2011 | 232 | 0.320 |
Why?
| | Analgesia, Patient-Controlled | 2 | 2006 | 28 | 0.320 |
Why?
| | Information Systems | 3 | 2021 | 18 | 0.320 |
Why?
| | Prosthesis Failure | 2 | 2014 | 534 | 0.310 |
Why?
| | Bone Resorption | 2 | 2019 | 96 | 0.300 |
Why?
| | Preoperative Care | 4 | 2020 | 146 | 0.300 |
Why?
| | Physicians | 3 | 2019 | 120 | 0.300 |
Why?
| | Visual Analog Scale | 3 | 2020 | 49 | 0.300 |
Why?
| | Severity of Illness Index | 7 | 2020 | 1240 | 0.300 |
Why?
| | Models, Anatomic | 3 | 2013 | 68 | 0.300 |
Why?
| | Academic Medical Centers | 1 | 2007 | 158 | 0.290 |
Why?
| | Foreign-Body Migration | 1 | 2006 | 19 | 0.290 |
Why?
| | Ankle Joint | 2 | 2019 | 44 | 0.290 |
Why?
| | Patient Readmission | 2 | 2018 | 129 | 0.290 |
Why?
| | Depression | 2 | 2021 | 516 | 0.290 |
Why?
| | Organ Preservation | 1 | 2005 | 10 | 0.290 |
Why?
| | Pain Management | 1 | 2007 | 139 | 0.280 |
Why?
| | Tennis Elbow | 2 | 2019 | 13 | 0.280 |
Why?
| | Bursa, Synovial | 1 | 2005 | 10 | 0.280 |
Why?
| | Electrocoagulation | 1 | 2005 | 14 | 0.280 |
Why?
| | Single-Blind Method | 5 | 2008 | 132 | 0.280 |
Why?
| | Burns | 1 | 2005 | 26 | 0.280 |
Why?
| | Sensitivity and Specificity | 5 | 2014 | 580 | 0.280 |
Why?
| | Cell Transplantation | 3 | 2010 | 28 | 0.280 |
Why?
| | Connective Tissue | 3 | 2013 | 28 | 0.270 |
Why?
| | Analysis of Variance | 7 | 2011 | 364 | 0.270 |
Why?
| | Materials Testing | 4 | 2017 | 140 | 0.270 |
Why?
| | Collagen Type III | 3 | 2015 | 14 | 0.270 |
Why?
| | Collagen Type I | 3 | 2015 | 19 | 0.270 |
Why?
| | Shoulder Impingement Syndrome | 3 | 2014 | 10 | 0.270 |
Why?
| | Posterior Cruciate Ligament | 3 | 2020 | 23 | 0.260 |
Why?
| | Equipment Design | 5 | 2017 | 198 | 0.260 |
Why?
| | Disease Progression | 3 | 2016 | 861 | 0.260 |
Why?
| | Ambulatory Surgical Procedures | 4 | 2016 | 81 | 0.260 |
Why?
| | Chondromalacia Patellae | 3 | 2009 | 4 | 0.260 |
Why?
| | Health Care Surveys | 2 | 2014 | 77 | 0.260 |
Why?
| | Rheumatic Diseases | 1 | 2005 | 61 | 0.250 |
Why?
| | Pectoralis Muscles | 2 | 2015 | 19 | 0.250 |
Why?
| | Pressure | 6 | 2015 | 71 | 0.250 |
Why?
| | Meta-Analysis as Topic | 7 | 2020 | 43 | 0.250 |
Why?
| | Casts, Surgical | 1 | 2003 | 6 | 0.240 |
Why?
| | Prevalence | 4 | 2015 | 544 | 0.240 |
Why?
| | Occlusive Dressings | 1 | 2003 | 1 | 0.240 |
Why?
| | Lacerations | 2 | 2013 | 16 | 0.240 |
Why?
| | Mesenchymal Stem Cell Transplantation | 2 | 2020 | 32 | 0.240 |
Why?
| | Risk Assessment | 6 | 2017 | 806 | 0.240 |
Why?
| | Osteolysis | 2 | 2016 | 141 | 0.240 |
Why?
| | Regression Analysis | 4 | 2014 | 319 | 0.240 |
Why?
| | Surgical Wound Infection | 2 | 2018 | 106 | 0.240 |
Why?
| | Health Surveys | 2 | 2021 | 102 | 0.240 |
Why?
| | Survival Rate | 3 | 2021 | 465 | 0.230 |
Why?
| | Aggrecans | 3 | 2019 | 200 | 0.230 |
Why?
| | Knee | 4 | 2020 | 46 | 0.230 |
Why?
| | Cyclooxygenase 2 Inhibitors | 1 | 2022 | 33 | 0.230 |
Why?
| | Synovial Membrane | 3 | 2013 | 79 | 0.230 |
Why?
| | Retinal Degeneration | 1 | 2021 | 5 | 0.220 |
Why?
| | Radio Waves | 4 | 2008 | 9 | 0.220 |
Why?
| | Health Status Indicators | 3 | 2012 | 82 | 0.220 |
Why?
| | Creatine | 1 | 2021 | 5 | 0.220 |
Why?
| | Placenta | 1 | 2021 | 16 | 0.220 |
Why?
| | Practice Guidelines as Topic | 2 | 2015 | 389 | 0.220 |
Why?
| | Electromyography | 3 | 2016 | 93 | 0.210 |
Why?
| | Collagen | 4 | 2013 | 111 | 0.210 |
Why?
| | Internship and Residency | 3 | 2021 | 201 | 0.210 |
Why?
| | Pregnancy | 2 | 2021 | 457 | 0.210 |
Why?
| | Private Practice | 2 | 2014 | 6 | 0.210 |
Why?
| | Amniotic Fluid | 1 | 2020 | 8 | 0.210 |
Why?
| | Polymers | 4 | 2019 | 38 | 0.210 |
Why?
| | Dermatologic Surgical Procedures | 1 | 2021 | 13 | 0.210 |
Why?
| | Dermis | 1 | 2020 | 8 | 0.210 |
Why?
| | Body Mass Index | 4 | 2020 | 458 | 0.200 |
Why?
| | Practice Management, Medical | 1 | 2020 | 3 | 0.200 |
Why?
| | Perioperative Period | 1 | 2020 | 13 | 0.200 |
Why?
| | Benzophenones | 3 | 2019 | 23 | 0.200 |
Why?
| | Education, Medical, Graduate | 2 | 2019 | 83 | 0.200 |
Why?
| | Polycarboxylate Cement | 3 | 2010 | 8 | 0.200 |
Why?
| | Ketones | 3 | 2019 | 16 | 0.200 |
Why?
| | Compressive Strength | 4 | 2008 | 37 | 0.200 |
Why?
| | Primary Cell Culture | 1 | 2020 | 25 | 0.200 |
Why?
| | Cross-Sectional Studies | 6 | 2021 | 986 | 0.200 |
Why?
| | Research | 1 | 2020 | 64 | 0.200 |
Why?
| | Diagnostic Imaging | 2 | 2015 | 98 | 0.200 |
Why?
| | Movement | 3 | 2018 | 167 | 0.200 |
Why?
| | Molar | 1 | 2019 | 1 | 0.200 |
Why?
| | Mandibular Nerve | 1 | 2019 | 4 | 0.200 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2020 | 20 | 0.190 |
Why?
| | Bone Diseases | 2 | 2019 | 25 | 0.190 |
Why?
| | Symptom Assessment | 1 | 2020 | 24 | 0.190 |
Why?
| | Models, Biological | 3 | 2019 | 428 | 0.190 |
Why?
| | ROC Curve | 4 | 2020 | 153 | 0.190 |
Why?
| | Temperature | 2 | 2018 | 85 | 0.190 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 55 | 0.190 |
Why?
| | Polyethylene Glycols | 3 | 2019 | 56 | 0.190 |
Why?
| | Self Report | 3 | 2019 | 225 | 0.190 |
Why?
| | Epinephrine | 3 | 2006 | 30 | 0.190 |
Why?
| | Ankle | 1 | 2019 | 18 | 0.190 |
Why?
| | Consensus | 1 | 2019 | 106 | 0.180 |
Why?
| | Gene Expression Profiling | 1 | 2020 | 183 | 0.180 |
Why?
| | Chronic Disease | 3 | 2012 | 544 | 0.180 |
Why?
| | Fracture Fixation, Internal | 1 | 2019 | 71 | 0.180 |
Why?
| | Polyurethanes | 2 | 2010 | 10 | 0.180 |
Why?
| | Feasibility Studies | 1 | 2020 | 281 | 0.180 |
Why?
| | Patients | 1 | 2019 | 26 | 0.180 |
Why?
| | Probability | 3 | 2007 | 104 | 0.180 |
Why?
| | Research Subjects | 1 | 2018 | 13 | 0.180 |
Why?
| | Fluoroscopy | 2 | 2011 | 54 | 0.180 |
Why?
| | Statistics, Nonparametric | 2 | 2010 | 156 | 0.180 |
Why?
| | Aging | 4 | 2022 | 1614 | 0.180 |
Why?
| | Infant | 1 | 2021 | 642 | 0.180 |
Why?
| | Mental Health | 1 | 2020 | 119 | 0.180 |
Why?
| | Delivery of Health Care | 1 | 2020 | 130 | 0.180 |
Why?
| | Propionibacterium acnes | 1 | 2018 | 7 | 0.180 |
Why?
| | Thyroidectomy | 1 | 1998 | 22 | 0.170 |
Why?
| | Carcinoma, Papillary | 1 | 1998 | 26 | 0.170 |
Why?
| | Doxycycline | 1 | 2018 | 23 | 0.170 |
Why?
| | Blood Specimen Collection | 1 | 2018 | 14 | 0.170 |
Why?
| | Odds Ratio | 4 | 2020 | 327 | 0.170 |
Why?
| | Horses | 2 | 2016 | 29 | 0.170 |
Why?
| | Pandemics | 1 | 2020 | 203 | 0.170 |
Why?
| | Surgery Department, Hospital | 1 | 1998 | 9 | 0.170 |
Why?
| | Prospective Payment System | 1 | 1998 | 4 | 0.170 |
Why?
| | Diagnosis-Related Groups | 1 | 1998 | 10 | 0.170 |
Why?
| | Durapatite | 1 | 1997 | 11 | 0.170 |
Why?
| | Coronavirus Infections | 1 | 2020 | 97 | 0.170 |
Why?
| | Biomedical Research | 1 | 2019 | 89 | 0.170 |
Why?
| | Pneumonia, Viral | 1 | 2020 | 102 | 0.170 |
Why?
| | Molecular Weight | 1 | 2017 | 58 | 0.170 |
Why?
| | Carboplatin | 1 | 1997 | 52 | 0.170 |
Why?
| | Medical Staff, Hospital | 1 | 1998 | 21 | 0.170 |
Why?
| | Thyroid Neoplasms | 1 | 1998 | 52 | 0.170 |
Why?
| | Medical Records | 1 | 1998 | 40 | 0.170 |
Why?
| | Histiocytoma, Benign Fibrous | 1 | 1997 | 5 | 0.170 |
Why?
| | Humeral Fractures | 1 | 2017 | 22 | 0.170 |
Why?
| | Paclitaxel | 1 | 1997 | 80 | 0.170 |
Why?
| | Pneumonia | 1 | 2018 | 74 | 0.160 |
Why?
| | Pyridones | 1 | 2017 | 19 | 0.160 |
Why?
| | Fever | 1 | 2017 | 38 | 0.160 |
Why?
| | Body Height | 3 | 2015 | 45 | 0.160 |
Why?
| | Osteoporosis | 1 | 2018 | 74 | 0.160 |
Why?
| | Bone Morphogenetic Protein 2 | 3 | 2012 | 45 | 0.160 |
Why?
| | Education, Medical, Continuing | 2 | 2013 | 47 | 0.160 |
Why?
| | Extracellular Matrix Proteins | 2 | 2015 | 176 | 0.160 |
Why?
| | Observer Variation | 3 | 2012 | 146 | 0.160 |
Why?
| | Gait | 2 | 2016 | 395 | 0.160 |
Why?
| | Achilles Tendon | 2 | 2014 | 23 | 0.160 |
Why?
| | Disclosure | 1 | 2016 | 19 | 0.150 |
Why?
| | Soft Tissue Neoplasms | 1 | 1997 | 53 | 0.150 |
Why?
| | Tensile Strength | 3 | 2019 | 31 | 0.150 |
Why?
| | Electronic Health Records | 1 | 2017 | 82 | 0.150 |
Why?
| | Immunohistochemistry | 2 | 2008 | 494 | 0.150 |
Why?
| | Head and Neck Neoplasms | 1 | 1997 | 137 | 0.150 |
Why?
| | Brain Concussion | 1 | 2016 | 14 | 0.150 |
Why?
| | Orthopedic Fixation Devices | 1 | 2016 | 24 | 0.150 |
Why?
| | Disability Evaluation | 3 | 2020 | 332 | 0.150 |
Why?
| | Deltoid Muscle | 1 | 2015 | 6 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 1 | 1997 | 207 | 0.150 |
Why?
| | Patient Compliance | 1 | 2017 | 200 | 0.140 |
Why?
| | Capsaicin | 1 | 2015 | 12 | 0.140 |
Why?
| | Rats, Sprague-Dawley | 2 | 2007 | 494 | 0.140 |
Why?
| | Bone Marrow Transplantation | 2 | 2010 | 40 | 0.140 |
Why?
| | Prosthesis-Related Infections | 1 | 2018 | 209 | 0.140 |
Why?
| | Arthrography | 2 | 2015 | 26 | 0.140 |
Why?
| | Thoracic Nerves | 1 | 2015 | 3 | 0.140 |
Why?
| | Mononeuropathies | 1 | 2015 | 3 | 0.140 |
Why?
| | Mice | 6 | 2021 | 1894 | 0.140 |
Why?
| | Paralysis | 1 | 2015 | 17 | 0.140 |
Why?
| | Bone-Patellar Tendon-Bone Grafts | 1 | 2014 | 4 | 0.140 |
Why?
| | Surgical Procedures, Operative | 2 | 2009 | 40 | 0.140 |
Why?
| | Anti-Bacterial Agents | 1 | 2018 | 412 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 1997 | 405 | 0.140 |
Why?
| | Palliative Care | 2 | 2007 | 146 | 0.130 |
Why?
| | Knee Dislocation | 2 | 2005 | 7 | 0.130 |
Why?
| | Musculoskeletal System | 1 | 2014 | 6 | 0.130 |
Why?
| | Societies, Medical | 1 | 2016 | 209 | 0.130 |
Why?
| | Ilium | 1 | 2014 | 29 | 0.130 |
Why?
| | Unnecessary Procedures | 1 | 2014 | 30 | 0.130 |
Why?
| | New England | 1 | 2014 | 4 | 0.130 |
Why?
| | Elementary Particles | 1 | 2014 | 5 | 0.130 |
Why?
| | Quantum Theory | 1 | 2014 | 6 | 0.130 |
Why?
| | Acupuncture | 1 | 2013 | 2 | 0.130 |
Why?
| | Guided Tissue Regeneration | 1 | 2013 | 11 | 0.130 |
Why?
| | Placebos | 1 | 2014 | 89 | 0.130 |
Why?
| | Hyperthermia, Induced | 3 | 2005 | 6 | 0.130 |
Why?
| | Models, Educational | 1 | 2013 | 41 | 0.130 |
Why?
| | Computer-Assisted Instruction | 1 | 2013 | 29 | 0.120 |
Why?
| | Medical Records Systems, Computerized | 1 | 2013 | 12 | 0.120 |
Why?
| | Guideline Adherence | 1 | 2014 | 77 | 0.120 |
Why?
| | Models, Theoretical | 1 | 2014 | 112 | 0.120 |
Why?
| | Cross-Over Studies | 1 | 2013 | 82 | 0.120 |
Why?
| | Acromioclavicular Joint | 1 | 2013 | 18 | 0.120 |
Why?
| | Primary Health Care | 1 | 2014 | 106 | 0.120 |
Why?
| | Longitudinal Studies | 1 | 2017 | 1452 | 0.120 |
Why?
| | Cell Death | 5 | 2007 | 68 | 0.120 |
Why?
| | Hospitalization | 1 | 2016 | 359 | 0.120 |
Why?
| | Bone Marrow Cells | 2 | 2020 | 63 | 0.120 |
Why?
| | Osteophyte | 2 | 2012 | 5 | 0.120 |
Why?
| | Stilbenes | 1 | 2012 | 8 | 0.120 |
Why?
| | Polyphenols | 1 | 2012 | 9 | 0.120 |
Why?
| | Reference Values | 3 | 2010 | 260 | 0.120 |
Why?
| | Cell Proliferation | 4 | 2019 | 232 | 0.120 |
Why?
| | ADAM Proteins | 1 | 2013 | 95 | 0.120 |
Why?
| | Receptors, Fibroblast Growth Factor | 1 | 2012 | 7 | 0.120 |
Why?
| | Chondrosarcoma | 1 | 2012 | 40 | 0.120 |
Why?
| | Fibroblast Growth Factor 2 | 1 | 2012 | 24 | 0.120 |
Why?
| | Bone Morphogenetic Protein 7 | 2 | 2012 | 65 | 0.120 |
Why?
| | Joint Prosthesis | 1 | 2013 | 77 | 0.120 |
Why?
| | Microscopy, Confocal | 4 | 2007 | 128 | 0.120 |
Why?
| | Goats | 2 | 2009 | 10 | 0.110 |
Why?
| | Vasoconstrictor Agents | 2 | 2003 | 31 | 0.110 |
Why?
| | Equipment Failure | 2 | 2017 | 50 | 0.110 |
Why?
| | Arm Injuries | 1 | 2012 | 11 | 0.110 |
Why?
| | Transforming Growth Factors | 1 | 2011 | 2 | 0.110 |
Why?
| | Platelet-Derived Growth Factor | 1 | 2011 | 7 | 0.110 |
Why?
| | Fibroblast Growth Factors | 1 | 2011 | 9 | 0.110 |
Why?
| | Braces | 2 | 2016 | 26 | 0.110 |
Why?
| | Ceramics | 1 | 2011 | 22 | 0.110 |
Why?
| | Osseointegration | 1 | 2012 | 72 | 0.110 |
Why?
| | Synovitis | 1 | 2011 | 22 | 0.110 |
Why?
| | Acute Disease | 2 | 2010 | 254 | 0.110 |
Why?
| | Age Distribution | 3 | 2016 | 110 | 0.110 |
Why?
| | Joint Capsule Release | 1 | 2011 | 6 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2012 | 121 | 0.100 |
Why?
| | Epiphyses | 2 | 2020 | 13 | 0.100 |
Why?
| | Work Capacity Evaluation | 1 | 2010 | 8 | 0.100 |
Why?
| | Hot Temperature | 2 | 2008 | 26 | 0.100 |
Why?
| | Resistance Training | 1 | 2010 | 8 | 0.100 |
Why?
| | Dissection | 1 | 2010 | 29 | 0.100 |
Why?
| | Software | 2 | 2021 | 74 | 0.100 |
Why?
| | Ultrasonography, Interventional | 1 | 2011 | 73 | 0.100 |
Why?
| | Comorbidity | 2 | 2018 | 562 | 0.100 |
Why?
| | Transplants | 1 | 2009 | 11 | 0.100 |
Why?
| | Transforming Growth Factor beta1 | 3 | 2015 | 42 | 0.100 |
Why?
| | Hypertrophy | 1 | 2009 | 20 | 0.100 |
Why?
| | Prosthesis Fitting | 1 | 2009 | 23 | 0.090 |
Why?
| | Fallopian Tube Diseases | 1 | 2009 | 1 | 0.090 |
Why?
| | Organ Size | 1 | 2009 | 122 | 0.090 |
Why?
| | Anesthetics | 1 | 2009 | 24 | 0.090 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 1997 | 840 | 0.090 |
Why?
| | Infertility, Female | 1 | 2009 | 26 | 0.090 |
Why?
| | Asepsis | 1 | 2008 | 3 | 0.090 |
Why?
| | Risk | 2 | 2020 | 228 | 0.090 |
Why?
| | Calcitonin Gene-Related Peptide | 1 | 2008 | 15 | 0.090 |
Why?
| | Substance P | 1 | 2008 | 19 | 0.090 |
Why?
| | Dogs | 2 | 2008 | 283 | 0.090 |
Why?
| | Models, Statistical | 1 | 2009 | 144 | 0.090 |
Why?
| | Body Weight | 1 | 2009 | 167 | 0.090 |
Why?
| | Torque | 3 | 2017 | 29 | 0.090 |
Why?
| | Axons | 1 | 2008 | 42 | 0.090 |
Why?
| | Elasticity | 1 | 2008 | 53 | 0.090 |
Why?
| | Transplantation | 1 | 2008 | 5 | 0.090 |
Why?
| | Histocytochemistry | 1 | 2008 | 34 | 0.090 |
Why?
| | Horse Diseases | 1 | 2008 | 7 | 0.090 |
Why?
| | Logistic Models | 2 | 2020 | 479 | 0.080 |
Why?
| | Egypt | 1 | 2007 | 3 | 0.080 |
Why?
| | Management Information Systems | 1 | 2007 | 3 | 0.080 |
Why?
| | Hip Joint | 1 | 2011 | 339 | 0.080 |
Why?
| | Smoking | 3 | 2018 | 202 | 0.080 |
Why?
| | Internal Fixators | 1 | 2007 | 53 | 0.080 |
Why?
| | Quality-Adjusted Life Years | 3 | 2014 | 25 | 0.080 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2006 | 4 | 0.080 |
Why?
| | Tissue Preservation | 1 | 2006 | 6 | 0.080 |
Why?
| | Arachidonic Acid | 1 | 2006 | 15 | 0.080 |
Why?
| | Ultrasonic Therapy | 1 | 2006 | 22 | 0.080 |
Why?
| | Collagen Type II | 2 | 2019 | 36 | 0.080 |
Why?
| | Mechanics | 1 | 2006 | 4 | 0.080 |
Why?
| | Drug Combinations | 1 | 2006 | 88 | 0.080 |
Why?
| | Forecasting | 2 | 2005 | 134 | 0.080 |
Why?
| | Muscle Weakness | 1 | 2006 | 36 | 0.080 |
Why?
| | Arthroscopes | 2 | 2007 | 9 | 0.080 |
Why?
| | Tissue and Organ Procurement | 1 | 2006 | 37 | 0.070 |
Why?
| | Medial Collateral Ligament, Knee | 1 | 2006 | 6 | 0.070 |
Why?
| | Jogging | 1 | 2005 | 3 | 0.070 |
Why?
| | Muscular Atrophy | 1 | 2005 | 9 | 0.070 |
Why?
| | Fractures, Compression | 1 | 2005 | 7 | 0.070 |
Why?
| | Glucosamine | 1 | 2005 | 15 | 0.070 |
Why?
| | Reactive Oxygen Species | 1 | 2006 | 133 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2019 | 174 | 0.070 |
Why?
| | Sulfur Radioisotopes | 1 | 2005 | 19 | 0.070 |
Why?
| | Education, Continuing | 1 | 2005 | 14 | 0.070 |
Why?
| | Sulfates | 1 | 2005 | 21 | 0.070 |
Why?
| | Joints | 1 | 2006 | 101 | 0.070 |
Why?
| | Chondroitin Sulfates | 1 | 2005 | 42 | 0.070 |
Why?
| | Fractures, Spontaneous | 1 | 2005 | 11 | 0.070 |
Why?
| | Equipment Safety | 1 | 2005 | 13 | 0.070 |
Why?
| | Bone Marrow Diseases | 1 | 2005 | 9 | 0.070 |
Why?
| | Osteonecrosis | 1 | 2005 | 19 | 0.070 |
Why?
| | Shoulder Fractures | 1 | 2005 | 25 | 0.070 |
Why?
| | Sex Distribution | 2 | 2016 | 89 | 0.070 |
Why?
| | Arthrometry, Articular | 2 | 2017 | 14 | 0.070 |
Why?
| | Fracture Fixation | 1 | 2005 | 26 | 0.070 |
Why?
| | Edema | 1 | 2005 | 40 | 0.070 |
Why?
| | Joint Capsule | 1 | 2005 | 45 | 0.070 |
Why?
| | Image Enhancement | 1 | 2005 | 63 | 0.070 |
Why?
| | Diet | 1 | 2006 | 202 | 0.070 |
Why?
| | Musculoskeletal Diseases | 1 | 2005 | 32 | 0.070 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2015 | 148 | 0.070 |
Why?
| | Drug Administration Schedule | 1 | 2005 | 257 | 0.070 |
Why?
| | Decision Support Techniques | 2 | 2014 | 55 | 0.070 |
Why?
| | Glycosaminoglycans | 2 | 2017 | 69 | 0.060 |
Why?
| | Prosthesis Design | 2 | 2019 | 511 | 0.060 |
Why?
| | Surface Properties | 2 | 2009 | 139 | 0.060 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2015 | 230 | 0.060 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2005 | 512 | 0.060 |
Why?
| | Mice, Inbred C57BL | 2 | 2017 | 548 | 0.060 |
Why?
| | Medical Illustration | 2 | 2015 | 20 | 0.060 |
Why?
| | Pulmonary Edema | 1 | 2003 | 14 | 0.060 |
Why?
| | Skin Temperature | 1 | 2003 | 2 | 0.060 |
Why?
| | Recombinant Proteins | 3 | 1999 | 295 | 0.060 |
Why?
| | Interleukin-1beta | 2 | 2013 | 59 | 0.060 |
Why?
| | Obesity | 1 | 2006 | 338 | 0.060 |
Why?
| | Confidence Intervals | 3 | 2009 | 102 | 0.060 |
Why?
| | Fascia Lata | 1 | 2002 | 6 | 0.060 |
Why?
| | Intraoperative Complications | 1 | 2003 | 76 | 0.060 |
Why?
| | Gene Expression | 2 | 2013 | 272 | 0.060 |
Why?
| | Transplantation Immunology | 1 | 2002 | 5 | 0.060 |
Why?
| | Indazoles | 1 | 2022 | 9 | 0.060 |
Why?
| | Microscopy, Electron, Scanning | 2 | 2002 | 81 | 0.060 |
Why?
| | Automation | 1 | 2021 | 12 | 0.060 |
Why?
| | Pyridines | 1 | 2022 | 50 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2021 | 42 | 0.050 |
Why?
| | Patient Admission | 2 | 2001 | 34 | 0.050 |
Why?
| | Inositol | 1 | 2021 | 8 | 0.050 |
Why?
| | Rats, Inbred Lew | 2 | 1999 | 13 | 0.050 |
Why?
| | Felypressin | 1 | 2001 | 1 | 0.050 |
Why?
| | Prilocaine | 1 | 2001 | 1 | 0.050 |
Why?
| | Metabolomics | 1 | 2021 | 21 | 0.050 |
Why?
| | Fetus | 1 | 2001 | 63 | 0.050 |
Why?
| | Imidazoles | 1 | 2022 | 74 | 0.050 |
Why?
| | Lipids | 1 | 2021 | 56 | 0.050 |
Why?
| | Chorion | 1 | 2020 | 2 | 0.050 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2020 | 4 | 0.050 |
Why?
| | Computers | 1 | 2021 | 26 | 0.050 |
Why?
| | Umbilical Cord | 1 | 2020 | 5 | 0.050 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2021 | 39 | 0.050 |
Why?
| | Chromatography, Liquid | 1 | 2020 | 21 | 0.050 |
Why?
| | Glucose | 1 | 2021 | 76 | 0.050 |
Why?
| | Tandem Mass Spectrometry | 1 | 2020 | 22 | 0.050 |
Why?
| | Expert Testimony | 1 | 2020 | 17 | 0.050 |
Why?
| | Osteogenesis | 2 | 1999 | 94 | 0.050 |
Why?
| | Registries | 2 | 2019 | 214 | 0.050 |
Why?
| | Steroids | 1 | 2020 | 30 | 0.050 |
Why?
| | Area Under Curve | 1 | 2020 | 79 | 0.050 |
Why?
| | Image Processing, Computer-Assisted | 2 | 2014 | 227 | 0.050 |
Why?
| | Personal Satisfaction | 1 | 2020 | 52 | 0.050 |
Why?
| | Heart Rate | 1 | 2001 | 161 | 0.050 |
Why?
| | Sports | 1 | 2020 | 36 | 0.050 |
Why?
| | Survival Analysis | 2 | 1998 | 379 | 0.050 |
Why?
| | Commerce | 1 | 2020 | 12 | 0.050 |
Why?
| | Ultrasonography | 1 | 2001 | 210 | 0.050 |
Why?
| | Proteomics | 1 | 2020 | 80 | 0.050 |
Why?
| | Elastic Modulus | 1 | 2019 | 15 | 0.050 |
Why?
| | Delphi Technique | 1 | 2019 | 26 | 0.050 |
Why?
| | Inflammation | 2 | 2012 | 360 | 0.050 |
Why?
| | Thrombin | 1 | 2019 | 14 | 0.050 |
Why?
| | Fibrinogen | 1 | 2019 | 33 | 0.050 |
Why?
| | Rehabilitation | 1 | 2019 | 15 | 0.050 |
Why?
| | Quality Assurance, Health Care | 1 | 2020 | 54 | 0.050 |
Why?
| | Blood Pressure | 1 | 2001 | 260 | 0.050 |
Why?
| | Morphine | 1 | 2020 | 80 | 0.050 |
Why?
| | Health Care Costs | 1 | 2020 | 81 | 0.050 |
Why?
| | Motion Therapy, Continuous Passive | 1 | 2019 | 5 | 0.050 |
Why?
| | Desiccation | 1 | 2019 | 6 | 0.050 |
Why?
| | Medicare | 1 | 2020 | 113 | 0.050 |
Why?
| | Platelet Count | 1 | 2019 | 25 | 0.050 |
Why?
| | Immobilization | 1 | 1999 | 12 | 0.050 |
Why?
| | Ischemia | 1 | 1999 | 35 | 0.040 |
Why?
| | Angiography | 1 | 1999 | 53 | 0.040 |
Why?
| | Bone Density | 1 | 2019 | 141 | 0.040 |
Why?
| | Carcinoma, Papillary, Follicular | 1 | 1998 | 2 | 0.040 |
Why?
| | Glucocorticoids | 1 | 2019 | 77 | 0.040 |
Why?
| | Image Interpretation, Computer-Assisted | 1 | 2019 | 84 | 0.040 |
Why?
| | Nitric Oxide | 2 | 2009 | 107 | 0.040 |
Why?
| | Lymph Node Excision | 1 | 1998 | 37 | 0.040 |
Why?
| | Carcinoma, Lobular | 1 | 1998 | 17 | 0.040 |
Why?
| | Tissue Banks | 1 | 2018 | 8 | 0.040 |
Why?
| | Carcinoma, Ductal, Breast | 1 | 1998 | 36 | 0.040 |
Why?
| | Forms and Records Control | 1 | 1998 | 11 | 0.040 |
Why?
| | Interferon-beta | 1 | 1997 | 8 | 0.040 |
Why?
| | Operating Rooms | 1 | 2018 | 18 | 0.040 |
Why?
| | Adjuvants, Immunologic | 1 | 1997 | 29 | 0.040 |
Why?
| | Adipose Tissue | 1 | 2019 | 98 | 0.040 |
Why?
| | Michigan | 1 | 2017 | 21 | 0.040 |
Why?
| | Documentation | 1 | 1998 | 27 | 0.040 |
Why?
| | Porosity | 1 | 1997 | 69 | 0.040 |
Why?
| | Femoral Neck Fractures | 1 | 1997 | 13 | 0.040 |
Why?
| | Fatal Outcome | 1 | 1997 | 75 | 0.040 |
Why?
| | Prosthesis Implantation | 1 | 1997 | 43 | 0.040 |
Why?
| | Fibrosis | 1 | 2017 | 53 | 0.040 |
Why?
| | Skin | 1 | 2018 | 136 | 0.040 |
Why?
| | Chi-Square Distribution | 1 | 1997 | 178 | 0.040 |
Why?
| | Tarsal Bones | 1 | 2016 | 7 | 0.040 |
Why?
| | Muscle Fatigue | 1 | 2017 | 11 | 0.040 |
Why?
| | Computer-Aided Design | 1 | 2017 | 15 | 0.040 |
Why?
| | Torso | 1 | 2017 | 8 | 0.040 |
Why?
| | Interleukins | 1 | 2017 | 42 | 0.040 |
Why?
| | Industry | 1 | 2016 | 11 | 0.040 |
Why?
| | Multiple Sclerosis | 1 | 1997 | 91 | 0.040 |
Why?
| | Titanium | 1 | 1997 | 204 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 1997 | 456 | 0.040 |
Why?
| | Online Systems | 1 | 2016 | 7 | 0.040 |
Why?
| | Early Ambulation | 1 | 2016 | 20 | 0.040 |
Why?
| | Current Procedural Terminology | 1 | 2016 | 14 | 0.040 |
Why?
| | Proprioception | 1 | 2016 | 21 | 0.040 |
Why?
| | History, 21st Century | 1 | 2016 | 39 | 0.040 |
Why?
| | Epidemiologic Methods | 1 | 2016 | 22 | 0.040 |
Why?
| | Apoptosis | 2 | 2012 | 292 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-sis | 1 | 2015 | 3 | 0.040 |
Why?
| | Hypertension | 1 | 2018 | 283 | 0.040 |
Why?
| | History, 20th Century | 1 | 2016 | 94 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2016 | 75 | 0.040 |
Why?
| | Injury Severity Score | 1 | 2015 | 22 | 0.040 |
Why?
| | Photography | 1 | 2015 | 18 | 0.040 |
Why?
| | Healthy Volunteers | 1 | 2015 | 50 | 0.040 |
Why?
| | Program Evaluation | 1 | 2016 | 153 | 0.040 |
Why?
| | Perioperative Care | 1 | 2016 | 75 | 0.030 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2015 | 28 | 0.030 |
Why?
| | Rupture, Spontaneous | 1 | 2014 | 8 | 0.030 |
Why?
| | Video Recording | 1 | 2015 | 52 | 0.030 |
Why?
| | False Negative Reactions | 1 | 2014 | 16 | 0.030 |
Why?
| | Occupational Injuries | 1 | 2015 | 9 | 0.030 |
Why?
| | Immunization | 1 | 1994 | 50 | 0.030 |
Why?
| | Thorax | 1 | 2014 | 16 | 0.030 |
Why?
| | Family | 1 | 1996 | 111 | 0.030 |
Why?
| | False Positive Reactions | 1 | 2014 | 40 | 0.030 |
Why?
| | Medical History Taking | 1 | 2014 | 26 | 0.030 |
Why?
| | Posture | 1 | 2015 | 92 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 60 | 0.030 |
Why?
| | Denmark | 1 | 2014 | 13 | 0.030 |
Why?
| | Hemostatic Techniques | 1 | 2014 | 10 | 0.030 |
Why?
| | Thigh | 1 | 2014 | 36 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2014 | 25 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2016 | 141 | 0.030 |
Why?
| | Mesons | 1 | 2014 | 5 | 0.030 |
Why?
| | Kidney Transplantation | 1 | 1996 | 141 | 0.030 |
Why?
| | Electrons | 1 | 2014 | 18 | 0.030 |
Why?
| | Anti-Infective Agents | 1 | 2014 | 59 | 0.030 |
Why?
| | Matrix Metalloproteinase 1 | 1 | 2013 | 7 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2013 | 39 | 0.030 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2013 | 36 | 0.030 |
Why?
| | Learning Curve | 1 | 2013 | 19 | 0.030 |
Why?
| | Muscle Strength Dynamometer | 1 | 2013 | 16 | 0.030 |
Why?
| | Acellular Dermis | 1 | 2013 | 7 | 0.030 |
Why?
| | Physical Conditioning, Animal | 1 | 2013 | 12 | 0.030 |
Why?
| | Precursor Cells, B-Lymphoid | 1 | 2013 | 2 | 0.030 |
Why?
| | Hip | 1 | 2013 | 40 | 0.030 |
Why?
| | Breast Neoplasms | 1 | 1998 | 442 | 0.030 |
Why?
| | Integrins | 1 | 2013 | 27 | 0.030 |
Why?
| | Analgesics | 1 | 2014 | 103 | 0.030 |
Why?
| | Metals | 1 | 2014 | 157 | 0.030 |
Why?
| | Intention to Treat Analysis | 1 | 2013 | 8 | 0.030 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 191 | 0.030 |
Why?
| | Clavicle | 1 | 2013 | 16 | 0.030 |
Why?
| | Interleukin-6 | 1 | 2013 | 120 | 0.030 |
Why?
| | Equipment Failure Analysis | 1 | 2013 | 116 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2013 | 30 | 0.030 |
Why?
| | Linear Models | 1 | 2013 | 276 | 0.030 |
Why?
| | Metabolism | 1 | 2012 | 11 | 0.030 |
Why?
| | Oncogene Protein v-akt | 1 | 2012 | 14 | 0.030 |
Why?
| | Plants | 1 | 2012 | 8 | 0.030 |
Why?
| | Peptide Hydrolases | 1 | 2012 | 21 | 0.030 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2012 | 27 | 0.030 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 32 | 0.030 |
Why?
| | Species Specificity | 1 | 2012 | 78 | 0.030 |
Why?
| | Neovascularization, Physiologic | 1 | 2012 | 29 | 0.030 |
Why?
| | Artificial Cells | 1 | 2012 | 1 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2012 | 70 | 0.030 |
Why?
| | Proteins | 1 | 2012 | 94 | 0.030 |
Why?
| | Secondary Prevention | 1 | 2012 | 67 | 0.030 |
Why?
| | Gamma Rays | 1 | 2012 | 17 | 0.030 |
Why?
| | Erythrocytes | 1 | 2012 | 31 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2013 | 399 | 0.030 |
Why?
| | Blood Platelets | 1 | 2012 | 52 | 0.030 |
Why?
| | Cell Line, Tumor | 1 | 2012 | 290 | 0.030 |
Why?
| | Transcription Factors | 1 | 2012 | 180 | 0.030 |
Why?
| | Device Removal | 1 | 2012 | 101 | 0.030 |
Why?
| | Coronary Disease | 1 | 1991 | 98 | 0.030 |
Why?
| | In Vitro Techniques | 2 | 2002 | 248 | 0.030 |
Why?
| | Behavior Therapy | 1 | 1991 | 86 | 0.030 |
Why?
| | Occupations | 1 | 2010 | 13 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2012 | 264 | 0.030 |
Why?
| | Neutrophils | 1 | 2011 | 133 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 351 | 0.020 |
Why?
| | Functional Laterality | 1 | 2010 | 96 | 0.020 |
Why?
| | Fertility Agents, Female | 1 | 2009 | 1 | 0.020 |
Why?
| | Hysterosalpingography | 1 | 2009 | 2 | 0.020 |
Why?
| | Nigeria | 1 | 2009 | 4 | 0.020 |
Why?
| | Signal Transduction | 1 | 2012 | 588 | 0.020 |
Why?
| | Clomiphene | 1 | 2009 | 9 | 0.020 |
Why?
| | Pregnancy Outcome | 1 | 2009 | 20 | 0.020 |
Why?
| | Hip Prosthesis | 1 | 1995 | 569 | 0.020 |
Why?
| | Sheep | 1 | 2008 | 38 | 0.020 |
Why?
| | Pregnancy Complications | 1 | 2009 | 57 | 0.020 |
Why?
| | Preservation, Biological | 1 | 2008 | 5 | 0.020 |
Why?
| | Cold Temperature | 1 | 2008 | 39 | 0.020 |
Why?
| | Nitric Oxide Synthase | 1 | 2008 | 48 | 0.020 |
Why?
| | Biopsy | 1 | 2008 | 283 | 0.020 |
Why?
| | Fractures, Bone | 1 | 2007 | 62 | 0.020 |
Why?
| | Mice, SCID | 1 | 2006 | 64 | 0.020 |
Why?
| | Cell Movement | 1 | 2006 | 119 | 0.020 |
Why?
| | Minicomputers | 1 | 2005 | 1 | 0.020 |
Why?
| | Selection Bias | 1 | 2005 | 9 | 0.020 |
Why?
| | Thermography | 1 | 2005 | 13 | 0.020 |
Why?
| | Body Temperature | 1 | 2005 | 74 | 0.020 |
Why?
| | Immunoassay | 1 | 1984 | 45 | 0.020 |
Why?
| | Intraoperative Period | 1 | 2002 | 39 | 0.010 |
Why?
| | Dental Care for Children | 1 | 2001 | 2 | 0.010 |
Why?
| | Dental Restoration, Permanent | 1 | 2001 | 2 | 0.010 |
Why?
| | Hospital Charges | 1 | 2001 | 23 | 0.010 |
Why?
| | Cell Nucleus | 1 | 2001 | 90 | 0.010 |
Why?
| | Polyglycolic Acid | 1 | 1999 | 2 | 0.010 |
Why?
| | Transplantation, Isogeneic | 1 | 1999 | 2 | 0.010 |
Why?
| | Drug Carriers | 1 | 1999 | 8 | 0.010 |
Why?
| | Lactic Acid | 1 | 1999 | 20 | 0.010 |
Why?
| | Rhode Island | 1 | 1998 | 3 | 0.010 |
Why?
| | Massachusetts | 1 | 1998 | 21 | 0.010 |
Why?
| | Axilla | 1 | 1998 | 17 | 0.010 |
Why?
| | Neoplasm Invasiveness | 1 | 1998 | 104 | 0.010 |
Why?
| | Lymphatic Metastasis | 1 | 1998 | 107 | 0.010 |
Why?
| | Proportional Hazards Models | 1 | 1998 | 390 | 0.010 |
Why?
| | Histocompatibility | 1 | 1996 | 5 | 0.010 |
Why?
| | Neoplasm Staging | 1 | 1998 | 481 | 0.010 |
Why?
| | HLA Antigens | 1 | 1996 | 20 | 0.010 |
Why?
| | Haplotypes | 1 | 1996 | 63 | 0.010 |
Why?
| | Equipment Reuse | 1 | 1995 | 4 | 0.010 |
Why?
| | Hospitals, Special | 1 | 1995 | 6 | 0.010 |
Why?
| | Cost Control | 1 | 1995 | 11 | 0.010 |
Why?
| | New York City | 1 | 1995 | 23 | 0.010 |
Why?
| | Stress, Physiological | 1 | 1994 | 26 | 0.010 |
Why?
| | Immunoglobulins | 1 | 1994 | 35 | 0.010 |
Why?
| | Program Development | 1 | 1995 | 76 | 0.010 |
Why?
| | Lymphocytes | 1 | 1994 | 113 | 0.010 |
Why?
| | Hypercholesterolemia | 1 | 1991 | 39 | 0.010 |
Why?
| | Reagent Kits, Diagnostic | 1 | 1984 | 20 | 0.000 |
Why?
| | Laboratories | 1 | 1984 | 28 | 0.000 |
Why?
| | Quality Control | 1 | 1984 | 50 | 0.000 |
Why?
| | Thyroxine | 1 | 1984 | 91 | 0.000 |
Why?
| | Triiodothyronine | 1 | 1984 | 113 | 0.000 |
Why?
|
|
Cole's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|